A study from the University of Michigan Health Rogel Cancer Center and Department of Pathology shows that further testing in renal cell carcinoma with an overexpression of gene TRIM63 could uncover a ...

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of ...

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in ...

At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Xencor's clear cell renal cell carcinoma treatment demonstrated evidence of anti-tumor activity in a phase 1 trial.

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

Researchers at The University of Texas MD Anderson Cancer Center, in collaboration with BostonGene, conducted the largest and ...

Merck and Eisai Announce WELIREG® Plus LENVIMA® Met Primary Endpoint of PFS in Certain Previously Treated Patients With ...

Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global ...

Ferroptosis, a regulated cell death mechanism, is emerging as a promising target for cancer therapy. The process is mediated by the activity of acyl-CoA synthetase family member 4 (ACSL4) protein.